Iginio C.
- Country
- Italy
- Department
- UOC UTIC - Emodinamica - Cardiologia
Research Overview
Data & Insights
Has run more than one trial at 0 of 3 partner sites.
Specializations
Hematologic Oncology
The investigator concentrates on Acute Myeloid Leukemia with FLT3 mutation, Acute Lymphoblastic Leukemia Philadelphia‑positive, Chronic Myeloid Leukemia in chronic phase, and Follicular Lymphoma as well as marginal‑zone and Hodgkin’s lymphoma.
- Targeted therapy for FLT3‑mutated AML
- Chemo‑free regimens for Ph+ ALL
- Nilotinib versus Imatinib strategies in CML
- Combination immunotherapy in marginal‑zone lymphoma
- Radiotherapy plus monoclonal antibodies in early follicular lymphoma
These efforts aim to improve remission depth and disease‑free survival in blood‑cancer patients.
Cardiovascular Therapeutics
Research activities address Acute Myocardial Infarction in STEMI patients with multivessel disease, coronary microvascular protection, and long‑term cardiovascular event reduction.
- Late sodium current inhibition after STEMI
- SGLT2 inhibitor impact on post‑MI atherosclerosis
- Survodutide evaluation for major adverse cardiovascular events
- CagriSema safety in heart‑vascular disease
- INaMICRON study on microcirculatory preservation
The focus is on preventing recurrent ischemic events and enhancing cardiac recovery.
Metabolic and Endocrine Disorders
The investigator explores therapeutic strategies for Type 2 Diabetes Mellitus, obesity, and overweight conditions, often in combination with cardiovascular risk management.
- SGLT2 inhibitor efficacy on glycemic targets
- Semaglutide plus reduced‑dose insulin comparison
- Tirzepatide impact on morbidity and mortality in obesity
- GliflOzin evaluation in elderly diabetic patients
- Metabolic outcomes in patients with concurrent cardiovascular disease
These projects target weight reduction, glycemic control, and cardiovascular risk mitigation.
Renal Immunology
A major area of interest is IgA Nephropathy, focusing on early corticosteroid intervention and renal protective combinations.
- Early corticosteroid therapy after kidney biopsy
- SGLT2 inhibitor plus RAS blockade versus steroids
- Proteinuria reduction strategies
- Renal lesion progression monitoring
- Biomarker‑guided therapeutic decisions
The goal is to preserve renal function while minimizing steroid‑related adverse effects.
Infectious Disease and Pandemic Response
Clinical work includes evaluation of treatments for SARS‑CoV‑2 infection, addressing both moderate and severe disease presentations.
- Baricitinib added to standard of care in severe COVID‑19
- Therapeutic impact on disease progression in hospitalized patients
- Mortality reduction in immunocompromised COVID‑19 cohorts
- Adaptive platform trial design for emerging infections
- Assessment of antiviral and anti‑inflammatory combinations
These initiatives aim to lower progression rates and improve survival during pandemic conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.